Canaan raises another $800M as it launches its next fund with an emphasis on biotech
Longtime VC player Canaan Partners has announced its newest fund and expects to funnel a good portion of that money into biotech over the next few years.
The technology and life sciences firm said it’s brought in a fresh $800 million to fund early-stage investing. This is Canaan’s 12th such fund and ties the amount it brought in back in June 2017, which it said at the time was a company record.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.